Jim, a 71-year-old former sales executive, was enjoying retirement when in 2014, he decided to find out why his PSA, which had been rising slowly, suddenly made several big jumps. His doctor recommended a prostate biopsy which revealed that Jim had prostate cancer, although it appeared to be slow growing according to traditional measures. Jim’s Gleason score was 3+3, indicating that it was low-grade and less likely to spread.
To get a clearer picture of the aggressiveness of Jim’s cancer, his doctor recommended the Oncotype DX Genomic Prostate Score (GPS) test. Jim was relieved when he received a low GPS result of 10. He felt comfortable choosing a program of active surveillance rather than immediate surgery or radiation – treatments that can often have life-changing side effects such as incontinence and impotence.
“I was relieved when genomic testing confirmed that my prostate cancer was slow growing.”
“I realized that it would be premature to pursue any aggressive treatment at that point,” says Jim. Six years later, Jim is secure in the knowledge that regular monitoring will alert him to any change in his condition. “I was relieved when genomic testing confirmed that my prostate cancer was slow growing. I would advise everyone to get all the information you can before you make a decision about your life and your body.” In the meantime, he is loving his life in Phoenix, Arizona, where he enjoys golf, photography, and spending time with his wife, children and grandchildren.
Back to Featured Stories